I'm speaking at GSK Oncology APAC summit. Audience - pharma. 30 -35 minutes talk - with a focus on the andrea cercek azur 1 data. at the end of the talk, they want to be able to speak to healthcare providers about the use of dostarlimab for this indication. on top of the dmmr rectal cancer data, they want me to share about the pathway - from diagnosis to treatment at our centre. what potential challenges there will be to give dostarlimab to these group of patients. incidence of rectal cancer - globally and locally incidence of dmmr cancers - tiny diagnosis - ihc, pcr, ngs (should i discuss about lynch here) background of the dmmr cohort - do poorly with chemo and rt (which trials?) success of anti-pd1 in colorectal cancer 100% ccr msk data - asco 2023 and then updates azur1 data challenges - evaluating ccr challenges - irtox! challenges - discordance - central and local ihc testing (i like to confirm with a second test) challenges - superifical biopsy - rebiopsy must (takes a longer time but i think no choice). challenges - real world evidence - not as good! (all the references for this please) access to treatment (not yet on cdl) what are all the other anti pd1 trials for this population - pls give a list the future - adding ctdna (what's a good reference for this?), what are the ongoing clinical trials?